Towards a better understanding of the complexities of myalgic encephalomyelitis/chronic fatigue syndrome and long COVID
WP Tate, MOM Walker, K Peppercorn… - International Journal of …, 2023 - mdpi.com
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex condition
arising in susceptible people, predominantly following viral infection, but also other stressful …
arising in susceptible people, predominantly following viral infection, but also other stressful …
A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with …
Background Low dose naltrexone (LDN) is used off-label by many individuals with
fibromyalgia to help manage their pain. There is no current systematic literature review …
fibromyalgia to help manage their pain. There is no current systematic literature review …
Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial
KD Bruun, R Christensen, K Amris… - The Lancet …, 2024 - thelancet.com
Background Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for
its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose …
its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose …
Efficacy of low-dose Naltrexone and predictors of treatment success or discontinuation in Fibromyalgia and other chronic pain conditions: A fourteen-year, enterprise …
CN Driver, RS D'Souza - Biomedicines, 2023 - mdpi.com
Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other
chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic …
chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic …
[HTML][HTML] Low-dose Naltrexone use for the management of post-acute sequelae of COVID-19
H Bonilla, L Tian, VC Marconi, R Shafer… - International …, 2023 - Elsevier
The global prevalence of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) stands at
approximately 43% among individuals who have previously had acute COVID-19. In …
approximately 43% among individuals who have previously had acute COVID-19. In …
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose …
A Colomer-Carbonell, JP Sanabria-Mazo… - BMJ open, 2022 - bmjopen.bmj.com
Introduction There is evidence that low-dose naltrexone (LDN;< 5.0 mg/day) reduces pain
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Introduction A significant proportion of individuals suffering from post COVID-19 condition
(PCC, also known as long COVID) can present with persistent, disabling fatigue similar to …
(PCC, also known as long COVID) can present with persistent, disabling fatigue similar to …
[图书][B] The long covid handbook
G Medinger, D Altmann - 2022 - books.google.com
Understand, manage, and treat Long Covid. Reports suggest that over 100m people around
the world are living with Long Covid (more than 1.5 m in the UK) yet reliable, clear …
the world are living with Long Covid (more than 1.5 m in the UK) yet reliable, clear …
[HTML][HTML] Effect of opioid receptor antagonist on mitigating tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-induced apoptolysis in pemphigus …
X Peng, S Wang, K Wu, C Cook, L Li, Z Wang… - Journal of …, 2024 - Elsevier
Pemphigus is a severe autoimmune blistering disease characterized by acantholysis
triggered by autoantibodies against desmoglein 1 and 3 (DSG1/3). Apoptosis plays a pivotal …
triggered by autoantibodies against desmoglein 1 and 3 (DSG1/3). Apoptosis plays a pivotal …
[HTML][HTML] Low-dose naltrexone in rheumatological diseases
JF De Carvalho, T Skare - Mediterranean Journal of Rheumatology, 2023 - cyberleninka.ru
Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At
lowdose naltrexone (LDN) has been used in several diseases including chronic pain and …
lowdose naltrexone (LDN) has been used in several diseases including chronic pain and …